| Name | Title | Contact Details |
|---|
MCRA is the leading global full-service medical device, diagnostics, and biologics CRO and consulting advisory firm. MCRA delivers to its client`s industry experience, integrating its six business value creators: regulatory, clinical research, reimbursement, healthcare compliance, quality assurance, and distribution logistics to provide a dynamic, market-leading effort from innovation conception to commercialization. MCRA`s integrated application of these key value-creating initiatives provides unparalleled value for its clients. MCRA has offices in Washington, DC, Hartford, CT, New York, NY, and Tokyo, Japan and serves nearly 1,000 clients globally. Its core focus areas of therapeutic experience include orthopedics, spine, biologics, cardiovascular, diagnostic imaging, wound care, artificial intelligence, dental, anesthesia, general surgery, digital health, neurology, robotics, oncology, general and plastic surgery, urology, and in vitro diagnostic (IVD) devices and medical device cybersecurity. MCRA places particular emphasis on its expertise working with companies in all stages of development and throughout the technology life cycle by ushering technologies from the conceptual pre-clinical stage to market approval.
Ashley Medical is a Mokena, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Home Care Specialists is a Haverhill, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Modern lifestyles and persistent near vision utilization cause a majority of patients to experience the reduced visual acuity and painful symptoms of eye misalignment – headaches, eye strain, neck and shoulder pain, motion sickness and dry eye sensation. Neurolens addresses common binocular vision issues using a three-step process. Step one is efficiently identifying patient symptomology using a basic online symptom screener that every patient can complete in minutes. This information goes directly to the Neurolens Measurement Device, Gen 2—or NMD2—ready for step two, which is accurately and objectively measuring the patient`s level of misalignment. The NMD2 is an objective, accurate and repeatable way to measure eye misalignment as small as 0.01 Prism Diopters. Most importantly, step three is correcting eye misalignment with a proven lens solution. Neurolenses address binocular vision issues by providing a contoured prism lens design that gradually delivers more prism in the lens corridor from distance to near. Neurolenses are proven to have a profound impact on a patient`s visual clarity and comfort. In fact, 93% of patients responded positively to wearing Neurolenses. Over 81% of patients suffering from chronic daily headaches reported their symptoms were substantially reduced or basically gone after wearing Neurolenses for 90 days. Neurolens—recognized in 2022 as one of the 30 fastest growing private companies in the healthcare industry by Inc. Magazine—is confident that appropriately addressing growing binocular vision issues will become a standard of care in this industry, unlocking dramatic patient outcomes and practice growth.
LED Dental traces its roots back to the mid-1990s, when company founder Peter Whitehead began performing oral cancer research in conjunction with the British Columbia Cancer Agency (BCCA). In 2000, Peter and a fellow BCCA researcher were awarded patents for groundbreaking technologies they developed for detecting oral cancer. Peter ultimately formed LED Medical Diagnostics Inc. and it operating subsidiary, LED Dental, to focus on the advancement of these technologies. LED Dental, in concert with the BCCA, ultimately co-developed the patented VELscope® Vx Enhanced Oral Assessment System, a tissue fluorescence visualization technology that received FDA and Health Canada clearance in 2006. Since then, there have been more than 12,000 VELscope Vx systems sold globally, and they have been used to perform more than 25 million oral examinations worldwide. In early 2014, LED Dental entered the dental imaging market in response to the explosive growth in dental CAD/CAM and the shift away from film-based systems to faster, more efficient and higher quality digital imaging solutions. We serve a previously unmet market demand for "open architecture" digital imaging technologies and we are rapidly growing a comprehensive portfolio of state-of-the-art offerings to meet this demand. Guiding our growth is a management team comprised some of the best minds from both the clinical and business sides of the dental industry. Drawing upon their decades of collective experience, they are identifying target technologies and product lines for our portfolio; building and managing our operations and sales teams; and developing a streamlined chain of communication that enables us to listen closely and serve the needs of our customers - and, in turn, enabling these clients to best serve their patients.